76 related articles for article (PubMed ID: 22948895)
1. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension.
Eechoute K; van der Veldt AA; Oosting S; Kappers MH; Wessels JA; Gelderblom H; Guchelaar HJ; Reyners AK; van Herpen CM; Haanen JB; Mathijssen RH; Boven E
Clin Pharmacol Ther; 2012 Oct; 92(4):503-10. PubMed ID: 22948895
[TBL] [Abstract][Full Text] [Related]
2. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
Diekstra MH; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
Eur Urol; 2015 Oct; 68(4):621-9. PubMed ID: 25930089
[TBL] [Abstract][Full Text] [Related]
3. Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib.
Beuselinck B; Lambrechts D; Van Brussel T; Wolter P; Cardinaels N; Joniau S; Lerut E; Karadimou A; Couchy G; Sebe P; Ravaud A; Zerbib M; Caty A; Paridaens R; Schöffski P; Verkarre V; Berger J; Patard JJ; Zucman-Rossi J; Oudard S
Acta Oncol; 2014 Oct; 53(10):1413-22. PubMed ID: 24874929
[TBL] [Abstract][Full Text] [Related]
4. Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662.
Diekstra MH; Klümpen HJ; Lolkema MP; Yu H; Kloth JS; Gelderblom H; van Schaik RH; Gurney H; Swen JJ; Huitema AD; Steeghs N; Mathijssen RH
Clin Pharmacol Ther; 2014 Jul; 96(1):81-9. PubMed ID: 24566734
[TBL] [Abstract][Full Text] [Related]
5. Greater Sensitivity of Blood Pressure Than Renal Toxicity to Tyrosine Kinase Receptor Inhibition With Sunitinib.
Lankhorst S; Baelde HJ; Kappers MH; Smedts FM; Hansen A; Clahsen-van Groningen MC; Sleijfer S; Mathijssen RH; Danser AH; van den Meiracker AH
Hypertension; 2015 Sep; 66(3):543-9. PubMed ID: 26195484
[TBL] [Abstract][Full Text] [Related]
6. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients.
Hall PS; Harshman LC; Srinivas S; Witteles RM
JACC Heart Fail; 2013 Feb; 1(1):72-8. PubMed ID: 24621801
[TBL] [Abstract][Full Text] [Related]
7. Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors.
Kloth JS; Pagani A; Verboom MC; Malovini A; Napolitano C; Kruit WH; Sleijfer S; Steeghs N; Zambelli A; Mathijssen RH
Br J Cancer; 2015 Mar; 112(6):1011-6. PubMed ID: 25742483
[TBL] [Abstract][Full Text] [Related]
8. Cardiac and Nephrological Complications Related to the Use of Antiangiogenic and Anti-Programmed Cell Death Protein 1 Receptor/Programmed Cell Death Protein 1 Ligand Therapy.
Stachyra-Strawa P; Szatkowska-Sieczek L; Cisek P; Gołębiowski P; Grzybowska-Szatkowska L
Genes (Basel); 2024 Jan; 15(2):. PubMed ID: 38397167
[TBL] [Abstract][Full Text] [Related]
9. Mechanism Underlying Triple VEGFR Inhibitor Tivozanib-Induced Hypertension in Mice Model.
Alanazi WA; Alanazi AS; El-Nagar DM; Aljuraybah AM; Alsanea S; Alharbi M
Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37259438
[TBL] [Abstract][Full Text] [Related]
10. Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension-Mechanisms and Mitigation.
Butel-Simoes LE; Haw TJ; Williams T; Sritharan S; Gadre P; Herrmann SM; Herrmann J; Ngo DTM; Sverdlov AL
Hypertension; 2023 Apr; 80(4):685-710. PubMed ID: 36756872
[TBL] [Abstract][Full Text] [Related]
11. Treatment and Implications of Vascular Endothelial Growth Factor Inhibitor-Induced Blood Pressure Rise: A Clinical Cohort Study.
van Dorst DCH; Kabadayi S; Oomen-de Hoop E; Danser AHJ; Mathijssen RHJ; Versmissen J
J Am Heart Assoc; 2023 Jan; 12(1):e028050. PubMed ID: 36583425
[TBL] [Abstract][Full Text] [Related]
12. Beyond eNOS: Genetic influence in NO pathway affecting drug response.
Esposito A; Cotta Filho CK; Lacchini R
Genet Mol Biol; 2022; 45(3 Suppl 1):e20220157. PubMed ID: 36264109
[TBL] [Abstract][Full Text] [Related]
13. Genome-Wide Meta-Analysis Identifies Variants in
Diekstra MHM; Swen JJ; van der Zanden LFM; Vermeulen SH; Boven E; Mathijssen RHJ; Fukunaga K; Mushiroda T; Hongo F; Oosterwijk E; Cambon-Thomsen A; Castellano D; Fritsch A; Donas JG; Rodriguez-Antona C; Ruijtenbeek R; Radu MT; Eisen T; Junker K; Roessler M; Jaehde U; Miki T; Böhringer S; Kubo M; Kiemeney LALM; Guchelaar HJ
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740506
[TBL] [Abstract][Full Text] [Related]
14. Polygenic Risk Scores for Blood Pressure to Assess the Risk of Severe Bevacizumab-Induced Hypertension in Cancer Patients (Alliance).
Quintanilha JCF; Etheridge AS; Graynor BJ; Larson NB; Crona DJ; Mitchell BD; Innocenti F
Clin Pharmacol Ther; 2022 Aug; 112(2):364-371. PubMed ID: 35527502
[TBL] [Abstract][Full Text] [Related]
15. VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications.
Camarda N; Travers R; Yang VK; London C; Jaffe IZ
Curr Oncol Rep; 2022 Apr; 24(4):463-474. PubMed ID: 35179707
[TBL] [Abstract][Full Text] [Related]
16. Nephrotoxicity of Anti-Angiogenic Therapies.
Van Wynsberghe M; Flejeo J; Sakhi H; Ollero M; Sahali D; Izzedine H; Henique C
Diagnostics (Basel); 2021 Apr; 11(4):. PubMed ID: 33916159
[TBL] [Abstract][Full Text] [Related]
17. Insulin Resistance and Pellino-1 Mediated Decrease in the Activities of Vasodilator Signaling Contributes to Sunitinib-Induced Hypertension.
Liu Y; Tang LL; Liang C; Wu MM; Zhang ZR
Front Pharmacol; 2021; 12():617165. PubMed ID: 33841146
[TBL] [Abstract][Full Text] [Related]
18. Etiology and management of hypertension in patients with cancer.
Mohammed T; Singh M; Tiu JG; Kim AS
Cardiooncology; 2021 Apr; 7(1):14. PubMed ID: 33823943
[TBL] [Abstract][Full Text] [Related]
19. Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients.
van Dorst DCH; Dobbin SJH; Neves KB; Herrmann J; Herrmann SM; Versmissen J; Mathijssen RHJ; Danser AHJ; Lang NN
Circ Res; 2021 Apr; 128(7):1040-1061. PubMed ID: 33793337
[TBL] [Abstract][Full Text] [Related]
20. Meta-Analysis of ABCG2 and ABCB1 Polymorphisms With Sunitinib-Induced Toxicity and Efficacy in Renal Cell Carcinoma.
Sun F; Chen Z; Yao P; Weng B; Liu Z; Cheng L
Front Pharmacol; 2021; 12():641075. PubMed ID: 33762959
[No Abstract] [Full Text] [Related]
[Next] [New Search]
